ALX Oncology Holdings Inc. (ALXO) reported positive results from an ongoing phase I/II investigator- sponsored study of evorpacept, in combination with Roche’s (RHHBY) Rituxan (rituximab) and Bristol Myers’ (BMY) Revlimid (lenalidomide) (R), to treat indolent and aggressive relapsed or refractory B-cell non- Hodgkin lymphoma (R/R B-NHL). The early to mid-stage study is sponsored and conducted by MD Anderson Cancer Center, which is based in Texas. ALX Oncology announced that, per findings, patients receiving ...